Eli Lilly’s Zepbound and Mounjaro now available in U.S. after shortages, FDA says

Demand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and rival Novo Nordisk to invest billions to ramp up manufacturing.

Previous post An ugly July jobs report revives talk of recession and bigger Fed rate cuts
Next post ‘Inside Out 2’ success is AMC’s saving grace in Q2, stock rises 3%